Detailed Coverage

Shivalik Rasayan to Raise ₹33 Crore Via Preferential Issue for R&D

The company proposes to issue equity shares and warrants, targeting total proceeds of ₹33 crore.

Reader Takeaway: Capital infusion for R&D; potential dilution for existing shareholders.

What Just Happened

Shivalik Rasayan Limited announced its intention to conduct a preferential issue of securities. This move requires approval from the company's members at an upcoming Extra-ordinary General Meeting (EGM). The issue includes 3,72,000 equity shares and 9,48,000 warrants, each at an issue price of ₹250 per instrument. The total expected proceeds are ₹33 crore, assuming full conversion of the warrants.

Why This Matters

The capital raised will be strategically deployed to strengthen the company's research and development (R&D) initiatives in pharmaceuticals and APIs, acquire necessary equipment, and enhance plant infrastructure. A portion is also allocated for general corporate purposes. This infusion of funds is intended to drive future growth and innovation.

The Backstory

Shivalik Rasayan operates in the pharmaceutical and chemical sectors, focusing on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company's strategy often involves expanding its manufacturing capabilities and R&D efforts to cater to evolving market demands.

What Changes Now

If approved, the preferential issue will increase the company's capital base. The majority of the funds, ₹18 crore, are designated for R&D activities, with ₹7 crore for R&D equipment and plant infrastructure. The remaining ₹8 crore will be used for general corporate purposes. Warrant holders will pay 25% upfront, with the balance due upon conversion within 18 months.

Risks to Watch

A key risk is the non-exercise of warrants by holders, which could lead to forfeiture of the upfront payment. Additionally, the issuance of new equity shares and potential conversion of warrants will result in dilution of existing shareholders' stakes.

Peer Comparison

Companies in the pharmaceutical and API sector frequently undertake capital raising exercises to fund R&D, capacity expansion, and acquisitions. This strategy is common for maintaining competitiveness and developing new product pipelines.

Context Metrics

• Total Expected Proceeds: ₹33 crore.
• Equity Shares to be Issued: 3,72,000.
• Warrants to be Issued: 9,48,000.
• Issue Price: ₹250 per instrument.
• R&D Allocation: ₹18 crore.
• Warrant Exercise Period: 18 months from allotment.

What to Track Next

Investors should closely monitor the outcome of the EGM scheduled for August 20, 2026, for approval of the preferential issue. Subsequent tracking of the utilization of funds towards R&D and infrastructure development, as well as the conversion status of the warrants, will be crucial.